MedTrace Logo

Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide

NCT00871585 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 340

Last updated 2010-04-15

No results posted yet for this study

Summary

Prospective, non-comparative, non-interventional, observational study to collect and analyse real life environment data on advanced prostate cancer patients receiving combination treatment of medical or surgical castration and bicalutamide according to routine medical practice in Croatia. The main aim is to evaluate change of PSA level and prescribing practices based on prostate cancer stage.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Ana Marija Gjurovic · AstraZeneca

  • Andreja Hasenohrl · AstraZeneca

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00871585 on ClinicalTrials.gov